Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655691 | 1.00 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046732 | 0.86 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23860164 | 0.84 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29943108 | 0.84 | CRBN (0.49) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25937533 | 0.84 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25937335 | 0.83 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL30010467 | 0.83 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30144199 | 0.83 | CRBN (0.67) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23860106 | 0.83 | CRBN (0.67) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24123455 | 0.82 | CRBN (0.55) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11414416-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3917517-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416246-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20240002382-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-11414416-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | CRBN 7/4885DDB1 3044/4885ALDH1A1 2817/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.